Peroxisome proliferator-activated receptor delta · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Peroxisome proliferator-activated receptor delta shows approved-linked disease relevance led by biliary liver cirrhosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q03181. Start with biliary liver cirrhosis, then reuse UniProt Q03181 as the stable protein anchor across project notes and exports.
Start with biliary liver cirrhosis, then reuse UniProt Q03181 as the stable protein anchor across project notes and exports.
Peroxisome proliferator-activated receptor delta shows approved-linked disease relevance led by biliary liver cirrhosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with biliary liver cirrhosis because it currently carries approved-linked support. Linked drugs include SELADELPAR LYSINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPeroxisome proliferator-activated receptor delta
Review this target as Peroxisome proliferator-activated receptor delta, mapped to UniProt Q03181. Sequence length is 441 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor delta as ChEMBL target CHEMBL3979, mapped to UniProt Q03181. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Peroxisome proliferator-activated receptor delta is the right protein anchor across sources, using UniProt Q03181 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why biliary liver cirrhosis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Peroxisome proliferator-activated receptor delta |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q03181 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Peroxisome proliferator-activated receptor delta |
| UniProt Accession | Q03181 |
| Component Type | Protein |
| Sequence Length | 441 aa |
Peroxisome proliferator-activated receptor delta
Review this target as Peroxisome proliferator-activated receptor delta, mapped to UniProt Q03181. Sequence length is 441 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Peroxisome proliferator-activated receptor delta shows approved-linked disease relevance led by biliary liver cirrhosis. 5 more disease programs remain visible in the same review block.
Start review with biliary liver cirrhosis because it currently carries approved-linked support. Linked drugs include SELADELPAR LYSINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL387921 | 10.99 | Ki | 0.0102 | Preclinical |
| CHEMBL390005 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL38943 | 10.32 | Ki | 0.048 | Clinical |
| CHEMBL230063 | 10.22 | EC50 | 0.06 | Preclinical |
| CHEMBL5931937 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL5955597 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL200732 | 9.8 | Ki | 0.16 | Preclinical |
| CHEMBL38943 | 9.74 | EC50 | 0.18 | Clinical |
| CHEMBL4755323 | 9.7 | EC50 | 0.2 | Preclinical |
| CHEMBL435523 | 9.52 | Ki | 0.3 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 268 | 744 | 6.8 |
| single protein format | 216 | 663 | 6.8 |
| assay format | 15 | 72 | 7.0 |
| tissue-based format | 2 | 2 | 8.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 120 | 475 | 6.8 |
| assay format | 55 | 417 | 7.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |